Valeant Pharmaceuticals
Submit the following individually:
• What FY 2015 metrics did Valeant guide for during H1 15 . You can also look for guidance figures in other transcripts and investor presentations during H1 15.
• What comparable GAAP results did the Company end up achieving for FY 15?
• Identify the three largest non-GAAP adjustments used to get to $486m in Q1 15 operating income.
• Explain what these adjustments represent and whether you believe they were appropriate adjustments to make for a key performance metric like non-GAAP operating income.